Abstract
A common characteristic of most biochemical processes is a high degree of specificity. For example, most enzymes and receptors will only bind compounds with very specific characteristics. However, some biochemical processes have evolved to be versatile. For example, drug-metabolizing enzymes can bind and metabolize a wide variety of substrates. In general, most processes involved in ADME (absorption, distribution, metabolism, and elimination) tend to be nonselective. Consequently, modeling these processes requires unique approaches. Camitro is developing an integrated platform of computational models for the prediction of ADME/Tox properties of pharmaceutical drug candidates. Our models permit the high-throughput analysis of virtual compounds or libraries before synthesis at very early stages in the drug discovery process, thereby reducing the need for and complementing the interpretation of iterative compound synthesis and experimentation cycles. An overview of our modeling efforts will be provided, focusing on models for the cytochrome P450 enzymes.
Biography
Ken Korzekwa is Vice President of Research at Camitro Corporation. He joined Camitro from the University of Pittsburgh, where he was Associate Professor of Medicine in the Center for Clinical Pharmacology and Director of the Center’s Drug Discovery Program from 1995-1999. His research activities at Pittsburgh focused on four major areas: enzyme kinetics of drug metabolism, in vitro-iv vivo correlations in drug metabolism, predictive models for toxicological risk assessment, and steroid metabolism. While at Pittsburgh he also provided consulting on multiple occasions to pharmacokinetics/drug metabolism groups at major pharmaceutical companies. Prior to joining the University of Pittsburgh, he spent three years as a Staff Fellow and PRAT Fellow in the Laboratory of Chemical Pharmacology, NHLBI, NIH, under Dr. James Gillette, and five years as a Senior Staff Fellow in the Laboratory of Molecular Carcinogenesis, National Cancer Institute, NIH. Dr. Korzekwa has been actively involved in theoretical and experimental studies of P450 metabolism for more than 10 years. He has published extensively on the enzymology and mechanism of cytochrome P450 mediated human drug metabolism and toxicity. He was the recipient of the Best Paper Award in 1990 in Drug Metabolism and Disposition awarded by the Drug Metabolism Division of the American Society for Pharmacology and Experimental Therapeutics. Dr. Korzekwa serves on the Editorial Review Board for the journals Chemical Research and Toxicology and Journal of Biochemical Toxicology. He received his Ph.D. in Medicinal Chemistry from the University of Washington and his undergraduate degree in Chemical Engineering from the University of New Mexico.
Regulation of Drug-Metabolizing Enzymes by Nuclear Receptor
Activation: Serious Considerations in Drug Development
Bingfang Yan, D.V.M., Ph.D. Associate Professor
Department of Biomedical Sciences
University of Rhode Island
41 Lower College Road
Kingston, RI 02881
Tel: (401) 874-5032
Fax: (401) 874-5048
Email: byan@uri.edu
Abstract Cytochrome P450 (CYP) enzymes rank first among the phase I biotransformation enzymes in terms of catalytic versatility and the number of xenobiotics they metabolize. Therefore, CYP enzymes determine the intensity and duration of action of drugs and play key roles in the detoxication and bioactivation of xenobiotics. Many therapeutical agents are shown to increase the expression of CYP enzymes, thus cause serious drug-drug interactions. The Food and Drug Administration requests all new drugs be tested for CYP induction, and pharmaceutical industries are very interested in establishing CYP induction profiles of drug candidates early so that appropriate decisions can be made for further development. Studies of molecular signaling have demonstrated that CYP induction is primarily achieved by receptor-mediated transactivation. These receptors include the aryl hydrocarbon receptor, the constitutive androstane receptor, the pregnane X receptor and the peroxisome proliferator-activated receptor-. In this presentation, the mechanisms of action of these receptors will be discussed, and receptor-based screening procedures will be described.
Biography
Bingfang Yan is an associate professor of Biomedical Sciences at the University of Rhode Island. He received D.V.M. degree in 1982 from Huazhong Agricultural University and Ph.D. degree in 1994 from the University of Kansas Medical Center. His research interest is in drug-metabolizing enzymes in general, cytochrome P450 systems and carboxylesterases in particular. His lab uses cellular and molecular techniques and animal models to study catalysis, prodrug activation and xenobiotic-regulation mediated by nuclear receptors. Currently he is the principal investigator for two major projects supported by the National Institutes of Health.
Kelvin W. Chan, Ph.D.
Head, eADME
Drug Metabolism & Pharmacokinetics
Aventis Pharmaceuticals, Inc.
Route 202-206
P.O. Box 6800
Bridgewater, NJ 08807-0800
Tel: (908) 231-3878
Fax: (908) 231-2594
Email: kelvin.chan@aventis.com
Abstract
Advances in genomics, proteomics, combinatorial chemistry, and high throughput screening have synergistically increased our ability to generate large number of compounds that show in vitro activity towards the pharmacological targets. This has created an enormous challenge for pharmaceutical companies to define strategies for selecting the most “drug-like” compounds for further development. Historically, 63% of chemical entities failed in development due to poor biopharmaceutical properties or toxicity. Consequently, the absorption, distribution, metabolism, excretion (ADME), and pharmacokinetic (PK) properties of lead candidates are being characterized and optimized increasingly early in the discovery phase. Unfortunately, the throughput of ADME and PK screens lags behind that of activity screening and will become one of the bottlenecks in optimizing drug candidates. This presentation will discuss a general strategy for screening ADME/PK properties of lead compounds and using liquid chromatography/mass spectrometry to increase the throughput of ADME/PK studies.
Biograhpy
Kelvin W. Chan is the Head of early ADME (US) of Drug Metabolism & Pharmacokinetics at Aventis Pharmaceuticals, Inc. He had held previous positions in Drug Safety & Metabolism and Analytical Chemistry at Wyeth-Ayerst Research (1990-2000) and Syntex Research (1984-1990). His research interests have included high throughput strategies to provide metabolism and pharmacokinetic input to the discovery and refinement of new drug candidates, and chemical structure elucidation by the various spectroscopic techniques. He graduated with a Ph.D. in Analytical Chemistry from the University of Illinois and received post-doctoral training at Cornell University. Kelvin was an elected officer of the North Jersey ACS Mass Spectrometry Discussion Group (Treasurer, 1992-1993; Chair-Elected, 1993-1994; Chairman, 1994-1995). He has more than 60 invited lectures, presentations at national and international conferences, or peer reviewed publications.
Rapid Access to Drug Synthesis via Catalytic and
Asymmetric Processes
Chris H. Senanayake, Ph. D.
Senior Director of Chemical Process Research, Sepracor Inc.
111 Locke Drive
Marlborough, MA 01752-7231
Phone: 508-357-7459
Fax: 508-357-7408
Email: csenanay@sepracor.com
Share with your friends: |